Klinische Wochenschrift

, Volume 64, Issue 24, pp 1281–1290

Myoadenylate deaminase deficiency: Successful symptomatic therapy by high dose oral administration of ribose

  • N. Zöllner
  • S. Reiter
  • M. Gross
  • D. Pongratz
  • C. D. Reimers
  • K. Gerbitz
  • I. Paetzke
  • T. Deufel
  • G. Hübner


A 55 years old patient suffering from exercise-induced muscle pain and stiffness due to primary myoadenylate deaminase deficiency has been successfully treated with D-ribose since 1984: single doses of 4 grams administered at the beginning of exercise prevented the symptoms completely; on continuation of exercise this dose had to be repeated all 10–30 min. Total doses of 50–60 g per day were tolerated without side-effects.

Key words

Myoadenylate-(adenylate-, AMP-)deaminase deficiency D-ribose, metabolism Dribose, untoward effects Hyperuricemia 



adenosine-5′-monophosphate, diphosphate, -triphosphate


guanosine-5′-diphosphate, -triphosphate




myoadenylate deaminase




Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Aragon JJ, Tornheim K, Lowenstein JM (1980) On a possible role of IMP in the regulation of phosphorylase activity in skeletal muscle. FEBS Lett 117:K56-K64PubMedGoogle Scholar
  2. 2.
    Aragon JJ, Tornheim K, Goodman MN, Lowenstein JM (1981) Replenishment of citric acid cycle intermediates by the purine nucleotide cycle in rat skeletal muscle. Curr Top Cell Regul 18:131–149PubMedGoogle Scholar
  3. 3.
    Atkinson DE (1968) The energy charge of the adenylate pool as a regulatory parameter. Interaction with feedback modifiers. Biochemistry 7:4030–4034PubMedGoogle Scholar
  4. 4.
    Bass A, Brdiczka D, Eyer P, Hofer S, Pette D (1969) Metabolic differentiation of distinct muscle types at the level of enzymatic organization. Eur J Biochem 10:198–206PubMedGoogle Scholar
  5. 5.
    Conn HO (1962) Studies on the origin and significance of blood ammonia. I. Effect of various anticoagulants on the blood ammonia determination. Yale J Biol Med 35:171–184PubMedGoogle Scholar
  6. 6.
    Deufel T, Wieland OH (1983) Sensitive assay of carnitine palmitoyl transferase activity in tissue homogenates with a modified spectrophotometric method for enzymatic carnitine determination. Clin Chim Acta 135:247–251PubMedGoogle Scholar
  7. 7.
    DiMauro S, Miranda AF, Hays AP, Franck WA, Hoffman GS, Schoenfeldt RS, Singh N (1980) Myoadenylate deaminase deficiency. Muscle biopsy and muscle culture in a patient with gout. J Neurol Sci 47:191–202PubMedGoogle Scholar
  8. 8.
    Dimond EG (1955) Inhibitory effect of heparin upon adenylic deaminase. J Lab Clin Med 46:807–808Google Scholar
  9. 9.
    Fishbein WN, Armbrustmacher VW, Griffin JL (1978) Myoadenylate deaminase deficiency: a new disease of muscle. Science 200:545–548PubMedGoogle Scholar
  10. 10.
    Fishbein WN, Griffin JL, Armbrustmacher VW (1980) Stain for skeletal muscle adenylate deaminase. An effective tetrazolium stain for frozen biopsy specimens. Arch Pathol Lab Med 104:462–466PubMedGoogle Scholar
  11. 11.
    Fishbein WN (1984) Human myoadenylate deaminase deficiency. Adv Exp Med Biol 165A:77–84Google Scholar
  12. 12.
    Fishbein WN (1985) Myoadenylate deaminase deficiency: inherited and acquired forms. Biochem Med 33:158–169PubMedGoogle Scholar
  13. 13.
    Fishbein WN (1986) Myoadenylate deaminase deficiency. In: Engel AG, Banker BQ (eds) Myology. McGraw-Hill, New York, pp 1745–1762Google Scholar
  14. 14.
    Ginsburg J, Boucher B, Beaconsfield P (1970) Hormonal changes during ribose-induced hypoglycemia. Diabetes 19:23–27PubMedGoogle Scholar
  15. 15.
    Goebel HH, Bardosi A, Conrad B, Kuhlendahl HD, DiMauro S, Rumpf KW (1986) Myoadenylate deaminase deficiency. Klin Wochenschr 64:342–347PubMedGoogle Scholar
  16. 16.
    Griebsch A, Zöllner N (1976) Renal uric acid excretion evaluated over periods of one day and one month using balance techniques in normal and hyperuricemic subjects. In: Silbernagl S, Lang F, Greger R (eds) Amino acid transport and uric acid transport. Thieme, Stuttgart, pp 236–243Google Scholar
  17. 17.
    Gross M, Reiter S, Zöllner N (1987) The metabolism of D-ribose administered continuously to healthy persons and to subjects with myoadenylate deaminase deficiency. Klin Wochenschr 65 (in print)Google Scholar
  18. 18.
    Henry RJ (1968) Clinical chemistry — principles and technics. Harper and Row, New York, pp 664–666Google Scholar
  19. 19.
    Heuckenkamp PU, Zöllner N (1972) Xylitbilanz während mehrstündiger Infusionen mit konstanten Zufuhrraten bei gesunden Menschen. Klin Wochenschr 50:1063–1065PubMedGoogle Scholar
  20. 20.
    Joosten E, van Bennekom C, Oerlemans F, De Bruyn C, Oei T, Trijbels J (1984) Myoadenylate deaminase deficiency: an enzyme defect in search of a disease. Adv Exp Med Biol 165A:85–89Google Scholar
  21. 21.
    Kelemen J, Rice DR, Bradley WG, Munsat TL, DiMauro S, Hogan EL (1982) Familial myoadenylate deaminase deficiency and exertional myalgia. Neurology 32:857–863PubMedGoogle Scholar
  22. 22.
    Lally EV, Friedman JH, Kaplan SR (1985) Progressive myalgias and polyarthralgias in a patient with myoadenylate deaminase deficiency. Arthritis Rheum 28:1298–1302PubMedGoogle Scholar
  23. 23.
    Lecky BRF (1983) Failure of D-ribose in myoadenylate deaminase deficiency. Lancet i:193Google Scholar
  24. 24.
    Lilienthal JL, Zierler KL, Folk BP, Buka R, Riley MJ (1950) A reference base and system for analysis of muscle constituents. J Biol Chem 182:501–508Google Scholar
  25. 25.
    Löffler W, Gröbner W, Wolfram G, Zöllner N (1983) Die endogene Harnsäuresynthese des Menschen. Verh Dtsch Ges Inn Med 89:678–679Google Scholar
  26. 26.
    Lowenstein JM (1972) Ammonia production in muscle and other tissues: the purine nucleotide cycle. Physiol Rev 52:382–414Google Scholar
  27. 27.
    Marini M, Zunica G, Franceschi C (1985) Inhibition of cell proliferation by D-ribose and deoxy-D-ribose. Proc Soc Exp Biol Med 180:246–257PubMedGoogle Scholar
  28. 28.
    Mondzac A, Ehrlich GE, Seegmiller JE (1965) An enzymatic determination of ammonia in biological fluids. J Lab Clin Med 66:526–531PubMedGoogle Scholar
  29. 29.
    Munsat TL (1970) A standardized forearm ischemic exercise test. Neurology 20:1171–1178PubMedGoogle Scholar
  30. 30.
    Patten BM (1982) Beneficial effect of D-ribose in patient with myoadenylate deaminase deficiency. Lancet i:1071Google Scholar
  31. 31.
    Patterson VH, Kaiser KK, Brooke MH (1983) Exercising muscle does not produce hypoxanthine in adenylate deaminase deficiency. Neurology 33:784–786PubMedGoogle Scholar
  32. 32.
    Pizzichini M, Marcolongo R, Marinello E (1980) Ribose tolerance in gouty patients. Adv Exp Med Biol 122A:81–86PubMedGoogle Scholar
  33. 33.
    Pongratz D (1976) Differentialdiagnose der Erkrankungen der Skelettmuskulatur anhand von Muskelbiopsien. Thieme, StuttgartGoogle Scholar
  34. 34.
    Pongratz D (1986) Myopathie bei AMP-Deaminase-Mangel. Klin Wochenschr 64 (suppl V):96–97PubMedGoogle Scholar
  35. 35.
    Reiter S, Simmonds HA, Webster DR, Watson AR (1983) On the metabolism of allopurinol. Formation of allopurinol-1-riboside in purine nucleoside phosphorylase deficiency. Biochem Pharmac 32:2167–2174Google Scholar
  36. 36.
    Sabina RL, Swain JL, Patten BM, Ashizawa T, O'Brien WE, Holmes EW (1980) Disruption of the purine nucleotide cycle. A potential explanation for muscle dysfunction in myoadenylate deaminase deficiency. J Clin Invest 66:1419–1423PubMedGoogle Scholar
  37. 37.
    Sabina RL, Swain JL, Olanow CW, Bradley WG, Fishbein WN, DiMauro S, Holmes EW (1984) Myoadenylate deaminase deficiency. Functional and metabolic abnormalities associated with disruption of the purine nucleotide cycle. J Clin Invest 73:720–730PubMedGoogle Scholar
  38. 38.
    Sahlin K, Palmskog G, Hultman E (1978) Adenine nucleotide and IMP contents of the quadriceps muscle in man after exercise. Pflügers Arch 374:193–198Google Scholar
  39. 39.
    Scholte HR, Busch HFM, Luyt-Houwen IEM (1981) Familial AMP deaminase deficiency with skeletal muscle type I atrophy and fatal cardiomyopathy. J Inher Metab Dis 4:169–170Google Scholar
  40. 40.
    Segal S, Foley J, Wyngaarden JB (1957) Hypoglycemic effect of D-ribose in man. Proc Soc Exp Biol Med 95:551–555PubMedGoogle Scholar
  41. 41.
    Segal S, Foley J (1958) The metabolism of D-ribose in man. J Clin Invest 37:719–735PubMedGoogle Scholar
  42. 42.
    Shumate JB, Katnik R, Ruiz M, Kaiser K, Frieden C, Brooke MH, Carroll JE (1979) Myoadenylate deaminase deficiency. Muscle and Nerve 2:213–216PubMedGoogle Scholar
  43. 43.
    Shumate JB, Kaiser KK, Carroll JE, Brooke MH (1980) Adenylate deaminase deficiency in a hypotonic infant. J Pediat 96:885–887PubMedGoogle Scholar
  44. 44.
    Sinkeler SPT, Daanen HAM, Wevers RA, Oei TL, Joosten EMG, Binkhorst RA (1985) The relation between blood lactate and ammonia in ischemic handgrip exercise. Muscle and Nerve 8:523–527Google Scholar
  45. 45.
    Sinkeler SPT, Joosten EMG, Wevers RA, Binkhorst RA, Oei TL (1985) Myoadenylate deaminase deficiency and McArdle's disease: plasma adenosine, inosine and hypoxanthine after ischemic forearm exercise. Pediat Res 19:776Google Scholar
  46. 46.
    Sinkeler S, Joosten E, Wevers R, Binkhorst R, Oei L (1986) Skeletal muscle adenosine, inosine and hypoxanthine release following ischaemic forearm exercise in myoadenylate deaminase deficiency and McArdle's disease. Adv Exp Med Biol 195 B:517–523Google Scholar
  47. 47.
    Sinkeler SPT, Joosten EMG, Wevers RA, Binkhorst RA, Oerlemans FT, van Bennekom CA, Coerwinkel MM, Oei TL (1986) Ischaemic exercise test in myoadenylate deaminase deficiency and McArdle's disease: measurement of plasma adenosine, inosine and hypoxanthine. Clin Science 70:399–401Google Scholar
  48. 48.
    Söling HD, Bernhard G, Kuhn A, Lück HJ (1977) Inhibition of phosphofructokinase by fructose 1,6-diphosphatase in mammalian systems: protein-protein interaction or fructose 1,6-diphosphate trapping? Arch Biochem Biophys 182:563–572PubMedGoogle Scholar
  49. 49.
    Stankova J, Rola-Pleszczynski M (1984) α-Fucose inhibits human mixed-lymphocyte culture reactions and subsequent suppressor cell generation. Cell Immunol 83:83–91PubMedGoogle Scholar
  50. 50.
    Sutton JR, Toews CJ, Ward GR, Fox IH (1980) Purine metabolism during strenuous muscular exercise in man. Metabolism 29:254–260PubMedGoogle Scholar
  51. 51.
    Swain JL, Sabina RL, Holmes EW (1983) Myoadenylate deaminase deficiency. In: Stanbury JB, Wyngaarden JB, Fredrickson DS, Goldstein JL, Brown MS (eds) The metabolic basis of inherited disease, 5th edn. McGraw-Hill, New York, pp 1184–1191Google Scholar
  52. 52.
    Swain JL, Hines JJ, Sabina RL, Harbury OL, Holmes EW (1984) Disruption of the purine nucleotide cycle by inhibition of adenylosuccinate lyase produces skeletal muscle dysfunction. J Clin Invest 74:1422–1427PubMedGoogle Scholar
  53. 53.
    Ulrich F (1983) Inhibition by specific monosaccharides of interleukin 2-induced thymocyte proliferation. Cell Immunol 80:241–256PubMedGoogle Scholar
  54. 54.
    Valen PA, Nakayama DA, Veum JA, Wortmann RL (1985) Myoadenylate deaminase deficiency: diagnosis by forearm ischemic exercise testing and plasma purine measurements. Pediat Res 19:779Google Scholar
  55. 55.
    Valen PA, Nakayama DA, Veum JA, Wortmann RL (1986) Myoadenylate deaminase deficiency: diagnosis by forearm ischemic exercise testing. Adv Exp Med Biol 195 B:525–528Google Scholar
  56. 56.
    Yoshino M, Murakami K (1985) AMP deaminase reaction as a control system of glycolysis in yeast. Role of ammonium ion in the interaction of phosphofructokinase and pyruvate kinase activity with the adenylate energy charge. J Biol Chem 260:4729–4732PubMedGoogle Scholar
  57. 57.
    Zimmer HG (1980) Restitution of myocardial adenine nucleotides: acceleration by administration of ribose. J Physiol (Paris) 76:769–775Google Scholar
  58. 58.
    Zöllner N, Gross M (1986) Myoadenylatdeaminase-Mangel. Erfolgreiche Therapie eines Falles mit Ribose bzw. Xylit. Klin Wochenschr 64 (Suppl V):34–35Google Scholar
  59. 59.
    Zunica G, Marini M, Brunelli MA, Chiricolo M, Franceschi C (1986) D-Ribose inhibits DNA repair synthesis in human lymphocytes. Biochem Biophys Res Commun 138:673–678PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1986

Authors and Affiliations

  • N. Zöllner
    • 1
  • S. Reiter
    • 1
  • M. Gross
    • 1
  • D. Pongratz
    • 2
  • C. D. Reimers
    • 2
  • K. Gerbitz
    • 3
  • I. Paetzke
    • 3
  • T. Deufel
    • 3
  • G. Hübner
    • 4
  1. 1.Medizinische Poliklinik der Universität MünchenGermany
  2. 2.Friedrich-Baur-Institut bei der Medizinischen Klinik Innenstadt der Universität MünchenGermany
  3. 3.Institut für Klinische Chemie des Städtischen Krankenhauses München-SchwabingGermany
  4. 4.Pathologisches Institut der Universität MünchenGermany

Personalised recommendations